Ambrilia Biopharma Inc. Announces European Licensing Partnership With TEVA For Its Lead Oncology Product, Octreotide
ABOUT OCTREOTIDE, SANDOSTATIN®LAR AND ACROMEGALY
ABOUT AMBRILIA BIOPHARMA